Technology
Health
Biotechnology

Translate Bio

$10.02
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.53 (-5.02%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Translate Bio and other stocks, options, ETFs, and crypto commission-free!

About

Translate Bio, Inc. engages in the research and development of therapeutic drugs. It focuses on developing medicines to treat diseases caused by protein or gene dysfunction. Read More Its lead product candidates include MRT5005 for the treatment of cystic fibrosis; and for the treatment of ornithine transcarbamylase deficiency. The company was founded by Arthur M. Krieg and Jeannie T. Lee in 2011 and is headquartered in Lexington, MA.

Employees
81
Headquarters
Lexington, Massachusetts
Founded
2011
Market Cap
453.85M
Price-Earnings Ratio
Dividend Yield
Average Volume
145.93K
High Today
$10.59
Low Today
$9.56
Open Price
$10.41
Volume
97.56K
52 Week High
$16.60
52 Week Low
$4.81

Collections

Technology
Health
Biotechnology
Research And Development
2018 IPO
US
North America

News

Yahoo FinanceMay 9

Translate Bio Announces First Quarter 2019 Financial Results and Provides Corporate Update

-- Completed dosing in single-ascending dose portion of Phase 1/2 clinical trial in cystic fibrosis; data expected 3Q19 -- LEXINGTON, Mass., May 09, 2019 (GLOBE NEWSWIRE) -- Translate Bio (TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced financial results for the first quarter ended March 31, 2019 and reviewed recent corporate achievements and updates. ...

137
Associated PressMay 1

Translate Bio Announces $47.5 Million Private Placement

LEXINGTON, Mass., May 01, 2019 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, announced today that it has entered into a securities purchase agreement with several institutional accredited investors for the private placement of 5,582,940 shares of common stock at a purchase price of $8.50 per share, yielding expected gross...

217
Associated PressApr 29

Translate Bio Announces Oral Presentation of mRNA Therapeutics in Models of Metabolic Disorders at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

LEXINGTON, Mass., April 29, 2019 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today presented preclinical results that demonstrate the potential of mRNA therapeutics as treatments for urea cycle disorders (UCDs) and organic acidemias (OAs). The oral presentation, entitled Treatment of Metabolic Disorders Using Lipid Nano...

60

Earnings

Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Available May 9, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.